Ultragenyx Pharmaceutical (NASDAQ:RARE) CEO Sells $1,240,411.20 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil Kakkis sold 54,404 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the completion of the sale, the chief executive officer owned 658,994 shares of the company’s stock, valued at $15,025,063.20. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ultragenyx Pharmaceutical Trading Down 1.2%

NASDAQ:RARE opened at $21.80 on Thursday. The firm has a market capitalization of $2.11 billion, a PE ratio of -3.73 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $42.37. The firm’s fifty day simple moving average is $23.56 and its 200 day simple moving average is $29.19.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm’s revenue was up 25.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.39) earnings per share. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RARE. Robert W. Baird reduced their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Wells Fargo & Company reduced their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. HC Wainwright dropped their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Jefferies Financial Group reduced their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Finally, Wedbush restated a “neutral” rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Sixteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $68.29.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional support remains in the register, which can help stabilize the float and provide long‑term demand for shares. Read More.
• Neutral Sentiment: Analyst coverage is still skewed toward buys and the company recently reported revenue beat but an EPS miss (Feb. 12). That mixed fundamental backdrop leaves the stock sensitive to news and revisions.
• Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and a securities class action has been filed alleging misstatements/omissions related to setrusumab; the lead‑plaintiff deadline (Apr. 6, 2026) concentrates attention on potential damages and litigation risk. Read More.
• Negative Sentiment: Regulatory/program risk amplified: Levi & Korsinsky highlights that RARE plunged ~42% after disclosure of a Phase III failure for setrusumab — that clinical setback remains the root cause of the stock’s heightened volatility and underpins many of the litigation claims. Read More.
• Negative Sentiment: Clustered insider selling: the CEO and several senior executives and officers disclosed large share sales (multiple filings show material blocks around $22.7–22.8), which often weighs on near‑term sentiment and raises questions for some investors. Read More.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares during the period. Norges Bank acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $29,004,000. Millennium Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 787.6% during the fourth quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock valued at $20,255,000 after acquiring an additional 781,431 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $22,560,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Ultragenyx Pharmaceutical by 599.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company’s stock worth $25,281,000 after purchasing an additional 720,256 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.